As the incidence of cardiovascular disease (CVD) is rising, it is becoming more and more important to assess risk factors for CVD, to reduce the incidence and mortality of the disease
As the incidence of cardiovascular disease (CVD) is rising, it is becoming more and more important to assess risk factors for CVD, to reduce the incidence and mortality of the disease.
Apolipoproteins are the main structural components of lipoproteins and have been linked to CVD risk.
Randox can offer a full lipoprotein profile including HDL, LDL, small dense LDL and apolipoproteins for CVD risk assessment.
The apo B/ apo A-I ratio has been used as an indicator of CVD risk.
Apolipoprotein A I (apo A-1) is the main component of HDL (the 'good' cholesterol).
Apo A-I levels are inversely proportional to atherosclerosis.
Apo B is a component of LDL (the 'bad' cholesterol).
Increased levels of apo B indicate increased CVD risk, even when total and LDL cholesterol are within normal ranges.
This may be due to an increase in small dense LDL, which is up to four times more atherogenic than large buoyant LDL.
Apo A-I and B as well as other apolipoproteins and lipoproteins are available from Randox as simple, highly accurate immunoturbidimetric tests for fully automated analysers in the routine clinical lab.
